Development asset linked to Ascendis Pharma in public FDA and regional records.
pharma · Hypoparathyroidism (HP) in Adults · Chronic hypoparathyroidism
Ascendis Pharma
Ascendis Pharma Bone Diseases A/S
Ascendis Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Palo Alto, USA HQ
2010 Founded
5 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 3
- Patents
- 12
Ascendis Pharma pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ascendis Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
palopegteriparatide
Systemic hormonal preparations (H05)US regulatory status: approved. Molecular target: Parathyroid hormone/parathyroid hormone-related peptide receptor.
- Target
- Parathyroid hormone/parathyroid hormone-related peptide receptor
- Mechanism
- Parathyroid hormone receptor agonist
-
Development asset linked to Ascendis Pharma in public FDA and regional records.